Immunogenic peptides and their use in immune disorders
US9249202B2 · kind B2 · utility
Assignees
Inventor
Key dates
| Filing date | Aug 13, 2007 |
| Grant date | Feb 2, 2016 |
| Priority date | — |
| Expiry date | Jun 6, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y401/01015
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The peptides of the invention comprise (i) a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class II major histocompatibility complex (MHC) determinant and recognized by a CD4+ T cell, more specifically, of an allergen or autoantigen, coupled, optionally, through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence. The peptides may be used for the prevention or treatment of immune disorders, more specifically, of allergic disorders or autoimmune diseases. The present invention thus provides methods of treatment or preventing immune disorders by using such peptides.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.